These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 21906966)

  • 21. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.
    Thompson JE; Moses D; Shnier R; Brenner P; Delprado W; Ponsky L; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
    J Urol; 2014 Jul; 192(1):67-74. PubMed ID: 24518762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved diagnostic accuracy with multiparametric magnetic resonance imaging of the breast using dynamic contrast-enhanced magnetic resonance imaging, diffusion-weighted imaging, and 3-dimensional proton magnetic resonance spectroscopic imaging.
    Pinker K; Bogner W; Baltzer P; Gruber S; Bickel H; Brueck B; Trattnig S; Weber M; Dubsky P; Bago-Horvath Z; Bartsch R; Helbich TH
    Invest Radiol; 2014 Jun; 49(6):421-30. PubMed ID: 24566292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.
    Sciarra A; Panebianco V; Ciccariello M; Salciccia S; Cattarino S; Lisi D; Gentilucci A; Alfarone A; Bernardo S; Passariello R; Gentile V
    Clin Cancer Res; 2010 Mar; 16(6):1875-83. PubMed ID: 20197480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy.
    Parivar F; Hricak H; Shinohara K; Kurhanewicz J; Vigneron DB; Nelson SJ; Carroll PR
    Urology; 1996 Oct; 48(4):594-9. PubMed ID: 8886066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy.
    Yuen JS; Thng CH; Tan PH; Khin LW; Phee SJ; Xiao D; Lau WK; Ng WS; Cheng CW
    J Urol; 2004 Apr; 171(4):1482-6. PubMed ID: 15017203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer.
    Lattouf JB; Grubb RL; Lee SJ; Bjurlin MA; Albert P; Singh AK; Ocak I; Choyke P; Coleman JA
    BJU Int; 2007 May; 99(5):1041-6. PubMed ID: 17437438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations.
    Panebianco V; Sciarra A; De Berardinis E; Busetto GM; Lisi D; Buonocore V; Gentile V; Di Silverio F; Passariello R
    Anticancer Res; 2011 Apr; 31(4):1399-405. PubMed ID: 21508392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
    Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer.
    Hara N; Okuizumi M; Koike H; Kawaguchi M; Bilim V
    Prostate; 2005 Feb; 62(2):140-7. PubMed ID: 15389803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inter-reader agreement of multi-parametric MR imaging for the detection of prostate cancer: evaluation of a scoring system.
    Quentin M; Arsov C; Röhlen S; Klasen J; Antoch G; Albers P; Blondin D
    Rofo; 2012 Oct; 184(10):925-9. PubMed ID: 22744328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic accuracy of MRI/MRSI for patients with persistently high PSA levels and negative TRUS-guided biopsy results.
    Bhatia C; Phongkitkarun S; Booranapitaksonti D; Kochakarn W; Chaleumsanyakorn P
    J Med Assoc Thai; 2007 Jul; 90(7):1391-9. PubMed ID: 17710982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level].
    Wetter A; Ajdukovic AN; Fliessbach K; Lehnert T; Engl T; Jacobi V; Vogl TJ
    Rofo; 2006 Apr; 178(4):385-90. PubMed ID: 16607587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical value of dynamic contrast-enhanced magnetic resonance imaging at 3.0T to detect prostate cancer.
    Zhang X; Quan X; Lu S; Huang F; Yang J; Chan Q; Lin T
    J Int Med Res; 2014 Oct; 42(5):1077-84. PubMed ID: 25091389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy.
    Komai Y; Numao N; Yoshida S; Matsuoka Y; Nakanishi Y; Ishii C; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    J Urol; 2013 Sep; 190(3):867-73. PubMed ID: 23542406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.
    Somford DM; Hamoen EH; Fütterer JJ; van Basten JP; Hulsbergen-van de Kaa CA; Vreuls W; van Oort IM; Vergunst H; Kiemeney LA; Barentsz JO; Witjes JA
    J Urol; 2013 Nov; 190(5):1728-34. PubMed ID: 23680307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
    Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
    BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
    Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
    AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
    Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
    Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.